^
    Back
    Association details:
    Biomarker:SMARCA4 mutation
    Cancer:Lung Cancer
    Drug:AU-19820 (SMARCA2 degrader)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    AACR 2021
    Title:

    1144 - Orally bioavailable SMARCA2 degraders with exceptional selectivity and potency

    Published date:
    03/10/2021
    Excerpt:
    AU-19820 demonstrated potent anti-proliferative activity in SMARCA4 mutant but not in SMARCA2/4 proficient cell lines. Additionally, the lead compound exhibited significant tumor growth inhibition in RERF-LC-A1 (SMARCA4 mutant lung cancer)…